Experimental studies on reproductive toxicologic effects of lamotrigine in mice
- 23 October 2003
- journal article
- research article
- Published by Wiley in Birth Defects Research Part B: Developmental and Reproductive Toxicology
- Vol. 68 (5) , 428-438
- https://doi.org/10.1002/bdrb.10042
Abstract
BACKGROUND: Virtually all antiepileptic drugs (AED) tested so far have been found to be teratogenic. The second generation AED possess a number of therapeutic advantages over the older ones. There are, however, very little data on their effects on embryonic development. A recent report suggests that lamotrigine (LTG) can be teratogenic to human fetuses. With only a few cases of prenatal exposure to LTG in the record, however, it has not been possible to establish a recognizable pattern of malformations in the infants of LTG-treated mothers.OBJECTIVES: The objectives of the present study were to evaluate the reproductive toxic effects of LTG RESULTS: Single (50–200 mg/kg) or multiple doses (25, 50, 75 mg/kg) of LTG were administered by intraperitoneal (i.p.) injection (note that the therapeutic administration is oral) to groups of TO mice on gestation day (GD) 7 or 8. Fetuses were collected on GD 18. Maternal toxic effects including a dose-related mortality, a high incidence of abortion, embryo lethality, congenital malformations and intrauterine growth retardation (IUGR) were observed in the LTG-treated group. Administration of LTG in multiple low doses resulted in a better maternal survival and increased incidence of embryonic resorption and malformations with increasing dose; IUGR was significant but not dose-dependent. The malformations characteristic of the LTG multiple low dose group fetuses included maxillary-mandibular hypoplasia, exencephaly, cleft palate, median facial cleft, urogenital anomalies and varying degrees of caudal regression. Skeletal malformations and developmental delay of the skeleton were observed both in single and multiple dose groups.CONCLUSIONS: The results of this study indicate that LTG administered i.p. at high doses can induce intrauterine growth retardation and at low multiple doses causes a dose-dependent increase in embryonic resorption, craniofacial and caudal malformations as well as maternal toxicity in the mouse. Previous studies in other laboratories have used oral route of exposure and concluded that there are no teratogenic effects of LTG at dose levels that are not maternally toxic. Birth Defects Res B 68:428–438, 2003.Keywords
This publication has 55 references indexed in Scilit:
- Novel anticonvulsant medications in developmentExpert Opinion on Investigational Drugs, 2002
- Teratogenic Potential of the Newer Antiepileptic DrugsCNS Drugs, 2002
- Treatment of Epilepsy in Women of Reproductive AgeClinical Pharmacokinetics, 2002
- Newer AnticonvulsantsDrugs, 2000
- Teratogenic effects of vigabatrinin TO mouse fetusesTeratology, 1997
- Sodium valproate augments spontaneous neural tube defects and axial skeletal malformations into mouse fetusesReproductive Toxicology, 1996
- Comments on “origin of abnormality in a human simelian foetus as elucidated by our knowledge of vertebrate development”Teratology, 1988
- The pathogenesis of sirenomelia: An editorial commentTeratology, 1988
- A critical comparison of the freehand razor‐blade dissection method according to Wilson with an in situ sectioning method for rat fetusesTeratogenesis, Carcinogenesis, and Mutagenesis, 1985
- Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndromeThe Journal of Pediatrics, 1976